From: Intravitreal dexamethasone implant for central retinal vein occlusion without macular edema
Observation group | IVD-treated group | p-value | |
---|---|---|---|
Patients/ eyes (N) | 10/10 | 10/10 | N/A |
Sex, female/ maleb (N) | 9/2 | 7/2 | 0.38 |
Involved eye, right/ leftb (N) | 6/5 | 3/6 | 0.67 |
Mean agea (y) | 51.7 ± 20.7 | 43.2 ± 12.2 | 0.15 |
Hypertensionb (N (%)) | 3 (27.3) | 1 (11.1) | 0.36 |
Type 2 diabetesb (N (%)) | 2 (18.2) | 1 (11.1) | 0.88 |
Hypercoagulopathy (N (%)) | 0 (0) | 0 (0) | N/A |
Systemic autoimmune/inflammation (N (%)) | 0 (0) | 0 (0) | N/A |
Mean BCVAa (logMAR) | 0.11 ± 0.23 | 0.12 ± 0.33 | 0.61 |
Mean IOPa (mmHg) | 14.3 ± 2.0 | 12.0 ± 3.2 | 0.44 |
Spherical equivalenta (diopter) | −0.60 ± 0.53 | −0.89 ± 0.34 | 0.27 |
Mean duration of the diseasea (weeks) | 3.6 ± 4.6 | 3.8 ± 3.3 | 0.06 |